Literature DB >> 18772845

PTEN at the crossroad of metabolic diseases and cancer in the liver.

Manlio Vinciguerra1, Michelangelo Foti.   

Abstract

The tumor suppressor PTEN is a phosphoinositide phosphatase regulating the PI3K/Akt signaling pathways and mutated or deleted in a variety of human cancers. Recent evidence indicates that dysregulated PTEN expression and activity in the liver critically affect hepatic insulin sensitivity and trigger the development of non-alcoholic fatty liver diseases. As well, PTEN expression/activity is also affected with HBV and HCV infection, or following alcohol-related injury. Finally, PTEN mutations/deletions or low PTEN expression are associated with diverse liver malignancies thus suggesting a critical role for PTEN in hepatic cancers. This review will focus on our current knowledge of the regulation of PTEN expression/activity and the role of this phosphatase in liver diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18772845

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  23 in total

1.  Association of PTEN gene polymorphisms with liver cancer risk.

Authors:  Hong-Guang Li; Fang-Feng Liu; Hua-Qiang Zhu; Xu Zhou; Jun Lu; Hong Chang; Jin-Hua Hu
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

2.  PTEN in liver diseases and cancer.

Authors:  Marion Peyrou; Lucie Bourgoin; Michelangelo Foti
Journal:  World J Gastroenterol       Date:  2010-10-07       Impact factor: 5.742

3.  Carcinogen-induced hepatic tumors in KLF6+/- mice recapitulate aggressive human hepatocellular carcinoma associated with p53 pathway deregulation.

Authors:  Mirko Tarocchi; Rebekka Hannivoort; Yujin Hoshida; Ursula E Lee; Diana Vetter; Goutham Narla; Augusto Villanueva; Moshe Oren; Josep M Llovet; Scott L Friedman
Journal:  Hepatology       Date:  2011-06-26       Impact factor: 17.425

Review 4.  Oxidative stress, insulin signaling, and diabetes.

Authors:  Justin L Rains; Sushil K Jain
Journal:  Free Radic Biol Med       Date:  2010-12-13       Impact factor: 7.376

5.  Down-regulation of PTEN by HCV core protein through activating nuclear factor-κB.

Authors:  Yong Zhang; Rong-Qing Li; Xu-Dong Feng; Yan-Hua Zhang; Li Wang
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

6.  Coactivation of AKT and β-catenin in mice rapidly induces formation of lipogenic liver tumors.

Authors:  Jimmy K Stauffer; Anthony J Scarzello; Jesper B Andersen; Rachel L De Kluyver; Timothy C Back; Jonathan M Weiss; Snorri S Thorgeirsson; Robert H Wiltrout
Journal:  Cancer Res       Date:  2011-02-15       Impact factor: 12.701

7.  Caffeine and the analog CGS 15943 inhibit cancer cell growth by targeting the phosphoinositide 3-kinase/Akt pathway.

Authors:  Charlotte E Edling; Federico Selvaggi; Ragheda Ghonaim; Tania Maffucci; Marco Falasca
Journal:  Cancer Biol Ther       Date:  2014-02-12       Impact factor: 4.742

8.  Transposon mutagenesis identifies genes driving hepatocellular carcinoma in a chronic hepatitis B mouse model.

Authors:  Nancy A Jenkins; Neal G Copeland; Emilie A Bard-Chapeau; Anh-Tuan Nguyen; Alistair G Rust; Ahmed Sayadi; Philip Lee; Belinda Q Chua; Lee-Sun New; Johann de Jong; Jerrold M Ward; Christopher Ky Chin; Valerie Chew; Han Chong Toh; Jean-Pierre Abastado; Touati Benoukraf; Richie Soong; Frederic A Bard; Adam J Dupuy; Randy L Johnson; George K Radda; Eric Cy Chan; Lodewyk Fa Wessels; David J Adams
Journal:  Nat Genet       Date:  2013-12-08       Impact factor: 38.330

Review 9.  HCV Proteins Modulate the Host Cell miRNA Expression Contributing to Hepatitis C Pathogenesis and Hepatocellular Carcinoma Development.

Authors:  Devis Pascut; Minh Hoang; Nhu N Q Nguyen; Muhammad Yogi Pratama; Claudio Tiribelli
Journal:  Cancers (Basel)       Date:  2021-05-19       Impact factor: 6.639

10.  Immunopositivity for histone macroH2A1 isoforms marks steatosis-associated hepatocellular carcinoma.

Authors:  Francesca Rappa; Azzura Greco; Christine Podrini; Francesco Cappello; Michelangelo Foti; Lucie Bourgoin; Marion Peyrou; Arianna Marino; Nunzia Scibetta; Roger Williams; Gianluigi Mazzoccoli; Massimo Federici; Valerio Pazienza; Manlio Vinciguerra
Journal:  PLoS One       Date:  2013-01-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.